Skip to main content
SpringerLink
Log in

sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy

  • Published:
Current Medical Science Aims and scope Submit manuscript

Summary

Recent studies suggested that serum secretory phospholipase A2 group IB (sPLA2-IB) was increased in idiopathic membranous nephropathy (IMN). However, the interference of high lipemia on the sPLA2-IB levels was not taken into account in these studies. The present study aimed to investigate the correlation between sPLA2-IB and lipemia, and the clinical merit of sPLA2-IB in the prediction of prognosis of IMN patients. A total of 64 IMN patients, 39 immunoglobulin A nephropathy (IgAN) patients and 64 healthy controls were included in the study. The levels of serum sPLA2-IB, lipemia and proteinuria were measured. Fifty IMN patients were followed up for 6 months. Pathologic stages were made for all IgAN and IMN patients. The results showed that the levels of serum sPLA2-IB, cholesterol and low-density lipoprotein cholesterol (LDL-C) were significantly higher, and the levels of albumin and high-density lipoprotein cholesterol (HDL-C) were significantly lower in IMN patients than in healthy controls and IgAN patients. Serum sPLA2-IB levels were also found to be higher in IgAN patients than in heathy controls, but the association of serum sPLA2-IB levels with proteinuria, cholesterol and albumin was only shown in IMN patients. Antibody against M-type receptor for secretory phospholipase A2 (PLA2R1) was positive in 81.3% IMN patients. Glomerular sPLA2-IB deposition, podocyte fused processes, and density deposition on thickened basement membrane were seen in IMN patients, but not in IgAN patients. IMN patients with lower sPLA2-IB and proteinuria levels were found to have better outcome after the 6-month follow-up. In IMN patients, sPLA2-IB levels were significantly increased in both serum and renal tissue. In conclusion, serum sPLA2-IB was closely correlated with proteinuria, albumin and cholesterol, and IMN patients with lower sPLA2-IB levels were more likely to achieve a better outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol, 2010,21(4):697–704

    Article  CAS  Google Scholar 

  2. Xiaofan H, Jing X, Chenni G, et al. New risk score for predicting progression of membranous nephropathy. J Transl Med, 2019,17(1):41

    Article  Google Scholar 

  3. Tang L, Yao J, Kong X, et al. Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases: A cross-sectional study in China. Nephrology, 2017,22(2):168–173

    Article  Google Scholar 

  4. Nie P, Chen R, Luo M, et al. Clinical and Pathological Analysis of 4910 Patients Who Received Renal Biopsies at a Single Center in Northeast China. Biomed Res Int, 2019,2019:6869179

    PubMed  PubMed Central  Google Scholar 

  5. Beck LJ, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009,361(1):11–21

    Article  CAS  Google Scholar 

  6. Li W, Guo Y, Zhang Z, et al. Comparison of 2 Anti-PLA2R Immunoassays for the Diagnosis of Primary Membranous Nephropathy. Lab Med, 2018,49(4):316–322

    Article  Google Scholar 

  7. Radice A, Trezzi B, Maggiore U, et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev, 2016,15(2):146–154

    Article  CAS  Google Scholar 

  8. Liu NJ, Chapman R, Lin Y, et al. Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. Nanoscale, 2016,8(23):11834–11839

    Article  CAS  Google Scholar 

  9. Granata F, Balestrieri B, Petraroli A, et al. Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol, 2003,131(3):153–163

    Article  CAS  Google Scholar 

  10. Jo EJ, Lee HY, Lee YN, et al. Group IB secretory phospholipase A2 stimulates CXC chemokine ligand 8 production via ERK and NF-kappa B in human neutrophils. J Immunol, 2004,173(10):6433–6439

    Article  CAS  Google Scholar 

  11. Peuravuori HJ, Funatomi H, Nevalainen TJ. Group I and group II phospholipases A2 in serum in uraemia. Eur J Clin Chem Clin Biochem, 1993,31(8):491–494

    CAS  PubMed  Google Scholar 

  12. Li, W, Zhang, M, Guo, Y, et al. Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy. Clin Chim Acta, 2018,482:178–184

    Article  CAS  Google Scholar 

  13. Pan Y, Wan J, Liu Y, et al. sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor. Sci Rep, 2014,4:6660

    Article  CAS  Google Scholar 

  14. Hollie NI, Konaniah ES, Goodin C, et al. Group 1B phospholipase A(2) inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice. Atherosclerosis, 2014,234(2):377–380

    Article  CAS  Google Scholar 

  15. Cash JG, Kuhel DG, Goodin C, et al. Pancreatic acinar cell-specific overexpression of group 1B phospholipase A2 exacerbates diet-induced obesity and insulin resistance in mice. Int J Obes (Lond), 2011,35(6):877–881

    Article  CAS  Google Scholar 

  16. Hollie NI, Hui DY. Group 1B phospholipase A(2) deficiency protects against diet-induced hyperlipidemia in mice. J Lipid Res, 2011,52(11):2005–2011

    Article  CAS  Google Scholar 

  17. Hunsaker J, La’Ulu SL, Wyness SP, et al. Lipemic interference of ceruloplasmin assays—An evaluation of lipid removal methods. Clin Chim Acta, 2018,480:71–78

    Article  CAS  Google Scholar 

  18. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant, 2011,26(8):2526–2532

    Article  CAS  Google Scholar 

  19. Zhang C, Li W, Wen J, et al. Autophagy is involved in mouse kidney development and podocyte differentiation regulated by Notch signalling. J Cell Mol Med, 2017,21(7):1315–1328

    Article  CAS  Google Scholar 

  20. Xiao T, Guan X, Nie L, et al. Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice. Mol Cell Biochem, 2014,394(1–2):145–154

    Article  CAS  Google Scholar 

  21. Moroni G, Depetri F, Del VL, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant, 2017,32(10):1691–1696

    CAS  PubMed  Google Scholar 

  22. Castro-Castro MJ, Candas-Estebanez B, Esteban-Salan M, et al. Removing Lipemia in Serum/Plasma Samples: A Multicenter Study. Ann Lab Med, 2018,38(6):518–523

    Article  CAS  Google Scholar 

  23. Yamaguchi M, Ando M, Katsuno T, et al. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan. Ren Fail, 2018,40(1):435–441

    Article  CAS  Google Scholar 

  24. Beck S, Beck G, Ostendorf T, et al. Upregulation of group IB secreted phospholipase A(2) and its M-type receptor in rat ANTI-THY-1 glomerulonephritis. Kidney Int, 2006,70(7):1251–60

    Article  CAS  Google Scholar 

  25. Beck LJ, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int, 2010,77(9):765–770

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China

    Li-yan Yang, Bin-bin Dai, Song-hua Lin, Jian-xin Wan & Yang-bin Pan

  2. Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, China

    Yang-bin Pan

  3. Department of Cardiology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China

    Yuan-sheng Wu

  4. Department of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China

    Hong Chen, Guo-ping Li & Xuan Tao

Authors
  1. Li-yan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuan-sheng Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin-bin Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Song-hua Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guo-ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xuan Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian-xin Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yang-bin Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jian-xin Wan or Yang-bin Pan.

Ethics declarations

The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.

Additional information

This study was funded by the National Natural Science Foundation of China (No. 81670635), Talents Training Program of Pudong Hospital Affiliated to Fudan University (No. PY202002) and Natural Science Foundation of Fujian Province of China (No. 2019J01441).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, Ly., Wu, Ys., Dai, Bb. et al. sPLA2-IB Level Correlates with Hyperlipidemia and the Prognosis of Idiopathic Membranous Nephropathy. CURR MED SCI 40, 683–690 (2020). https://doi.org/10.1007/s11596-020-2246-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-020-2246-5

Key words

Search

Navigation